Entering text into the input field will update the search result below

Why Do We Keep Buying Takeda Pharmaceutical Shares

Nathan Aisenstadt profile picture
Nathan Aisenstadt


  • Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year.
  • Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on-quarter.
  • Takeda Pharmaceutical's dividend yield is 4.14%, higher than pharmaceutical industry giants Pfizer, AbbVie, and Merck.
  • In October 2022, a Japanese company announced that the FDA had accepted the sBLA application for the potential use of Takhzyro for prophylaxis to prevent attacks of HAE in children aged 2 to 12 years.
  • On March 18, 2023, the leader of the Japanese pharmaceutical industry published the results of a clinical study, according to which TAK-279 demonstrated excellent efficacy data and a favorable safety profile in patients with moderate to severe plaque psoriasis.
Portrait of female scalp massager

Yoshiyoshi Hirokawa/DigitalVision via Getty Images

Takeda Pharmaceutical (NYSE:TAK), Japan's largest pharmaceutical company and one of the leaders in the pharmaceutical industry, has a diverse portfolio of prescription drugs with competitive advantages in various therapeutic areas, including oncology, gastroenterology, and neuroscience.

In recent years, Takeda has faced

This article was written by

Nathan Aisenstadt profile picture
I am an independent research analyst focused on finding undervalued assets with above-average growth rates and developments that can dramatically improve the company's financial position. When investing, I use medium-term and long-term trading strategies that take into account psychological and behavioral variables and are able to mitigate the risks associated with macroeconomic and geopolitical instability.The main sectors of analysis are industrials, consumer staples, technology, and healthcare.When analyzing assets in the healthcare sector, in addition to examining their financial position, I delve into the safety and efficacy data of the company's product candidates from preclinical and clinical studies, allowing me to evaluate their commercial prospects. While the education received at the Hebrew University of Jerusalem contributes to a comprehensive and detailed analysis of biotechnological and physicochemical processes used in the production of goods in the agricultural, oil and gas, and chemical industries. As a result, it allows me to find the most promising assets in a rapidly changing market and publish meaningful articles on Seeking Alpha.My e-mail for any questions and suggestions: aisenathan@gmail.com

Analyst’s Disclosure: I/we have a beneficial long position in the shares of TAK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (10)

Adding color to the Editor's note: Takeda's ADRs (ticker: TAK) do trade on the NYSE, a major US stock exchange. Of course, its main listing is on the Tokyo Stock Exchange.
Like the company, but it’s stock price has languished and the foreign taxes on the dividend are very high
AGTC Ventures profile picture
Have worked with them since Millenium was M&A'd as their oncology group locally, long before the expansion. IT's a solid stock pick as much as Pfizer as of late.
Reading is never enough profile picture
I like Tak.and own 2000 shares.it is quite solid,with a good dividend.but it is not moving higher.for me it is ok.but for quick gains it is not.
Why you would buy this for 22 P/E on earnings which are the same as 20 years ago when you can buy Merck for P/E 13 on dips?

So far it was deteriorating company for 15 years. Only good about this company is EBITDA in recent years but I still have word of Warren Buffett in my mind that EBITDA is another word for bullshit earnings snd total nonsence.

Based on P/E it is not a good investment and you get better deals with BMY, MRK and Sanofi.
check your revenue numbers....$ 8M in Q3?
@Mogul Master $8,354 million is $8.3 billion.
Share price hasn’t moved on three years. It’s a lot like $rhbby,
Nathan Aisenstadt profile picture
@deadhead213 Greetings.

Everything comes to an end sooner or later.

Thanks for the comment.
@Nathan Aisenstadt been following $TAK for years and it’s definitely not moving higher at this point in time. Go back to 2020 and see for yourself
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About TAK

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on TAK

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.